- Home
- BSM vs CORT Comparison
BSM vs CORT Comparison
Compare BSM & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSM | CORT |
|---|---|---|
| Founded | 1876 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2015 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BSM | CORT |
|---|---|---|
| Price | $14.15 | $42.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $14.00 | ★ $107.20 |
| AVG Volume (30 Days) | 413.3K | ★ 1.9M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | $469,919,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $13.19 | $26.08 |
| Revenue Next Year | $10.45 | $31.04 |
| P/E Ratio | ★ $12.82 | $51.06 |
| Revenue Growth | 8.35 | ★ 12.79 |
| 52 Week Low | $11.90 | $28.66 |
| 52 Week High | $15.49 | $91.00 |
Technical Indicators
Market Signals| Indicator | BSM | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 30.75 | 62.74 |
| Support Level | $13.07 | $32.95 |
| Resistance Level | $15.33 | $47.06 |
| Average True Range (ATR) | 0.32 | 2.88 |
| MACD | -0.13 | 0.78 |
| Stochastic Oscillator | 10.69 | 52.27 |
Price Performance
Historical ComparisonAbout BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.